ISSN 2564-7784 | E-ISSN 2564-7040
Case Report
Diabetic Ketoacidosis Occurring in Patient on Newly Started Insulin Glargine U300
1 Department of Internal Medicine, Division of Endocrinology and Metabolism, Selçuk University School of Medicine, Konya, Turkey  
Eur J Ther 2018; 24: 266-267
DOI: 10.5152/EurJTher.2017.293
Key Words: Glargine U300, diabetic ketoacidosis, pharmacokinetic

Insulin glargine U300 is a 3-fold, concentrated, long-acting insulin analog providing a more stable effect compared with insulin glargine U100. However, stable plasma insulin concentration is reached on day 4 of the treatment. Patients with type 1 and type 2 diabetes mellitus with decreased insulin reserve are at an increased risk of diabetic ketoacidosis when there is insufficient exogenous plasma insulin concentration. Herein, we present a case of diabetic ketoacidosis occurring in a patient with insulin glargine U300 and emphasize the pharmacokinetic properties of insulin glargine U300.

Key Words
AVES | Copyright © 2018 European Journal of Therapeutics | Latest Update: 11.03.2019